INMB
vs
S&P 500
INMB
S&P 500
Over the past 12 months, INMB has underperformed S&P 500, delivering a return of -60% compared to the S&P 500's +14% growth.
Stocks Performance
INMB vs S&P 500
Performance Gap
INMB vs S&P 500
Performance By Year
INMB vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
INmune Bio Inc
Glance View
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 10 full-time employees. The company went IPO on 2019-02-04. The firm is focused on developing and commercializing its product candidates to treat diseases where the innate immune system is not functioning normally and contributing to the patient's disease. Its drug candidates include INKmune, INB03, and XPro1595 (XPro). The company has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble tumor necrosis factor alpha (TNF), a driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is being developed for Alzheimer's and treatment-resistant depression (XPro) and cancer (INB03). The Natural Killer (NK) Cell Priming Platform includes INKmune for priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic malignancies, solid tumors, and chronic inflammation.
